RESTART C0168Z05 Rheumatoid Arthritis Study
A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Graz-Eggenberg, Austria
-
Wien, Austria
-
-
-
-
-
Hamilton Ontario, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Newfoundland and Labrador
-
St. John'S, Newfoundland and Labrador, Canada
-
-
Ontario
-
Toronto, Ontario, Canada
-
-
-
-
-
Helsinki, Finlandia
-
-
-
-
-
Bordeaux Cedex, Francia
-
Limoges, Francia
-
Montivilliers, Francia
-
Orleans, Francia
-
-
-
-
-
Frankfurt, Germania
-
Holdenfelde, Germania
-
Leipzig, Germania
-
Muenchen, Germania
-
München, Germania
-
Ratingen, Germania
-
-
-
-
-
Ashkelon, Israele
-
Beer Yaakov, Israele
-
Haifa, Israele
-
Kfar Saba, Israele
-
Ramat Gan, Israele
-
Rehovot, Israele
-
Tel-Aviv, Israele
-
-
-
-
-
Alkmaar, Olanda
-
-
-
-
-
Leeds, Regno Unito
-
London, Regno Unito
-
Wigan, Regno Unito
-
-
-
-
-
Madrid, Spagna
-
Oviedo, Spagna
-
Santiago De Compostela, Spagna
-
-
-
-
Alabama
-
Huntsville, Alabama, Stati Uniti
-
-
Arizona
-
Paradise Valley, Arizona, Stati Uniti
-
Tucson, Arizona, Stati Uniti
-
-
California
-
Santa Monica, California, Stati Uniti
-
-
Connecticut
-
Bridgeport, Connecticut, Stati Uniti
-
-
Delaware
-
Lewes, Delaware, Stati Uniti
-
-
Florida
-
Boca Raton, Florida, Stati Uniti
-
Palm Harbor, Florida, Stati Uniti
-
Tamarac, Florida, Stati Uniti
-
Vero Beach, Florida, Stati Uniti
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti
-
-
Illinois
-
Moline, Illinois, Stati Uniti
-
Springfield, Illinois, Stati Uniti
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti
-
-
Maryland
-
Wheaton, Maryland, Stati Uniti
-
-
Michigan
-
Saint Clair Shores, Michigan, Stati Uniti
-
-
Minnesota
-
Eagan, Minnesota, Stati Uniti
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti
-
Springfield, Missouri, Stati Uniti
-
-
New Jersey
-
Berkeley Heights, New Jersey, Stati Uniti
-
Freehold, New Jersey, Stati Uniti
-
-
New York
-
Albany, New York, Stati Uniti
-
Syracuse, New York, Stati Uniti
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti
-
-
Ohio
-
Columbus, Ohio, Stati Uniti
-
Mayfield, Ohio, Stati Uniti
-
Middleburg Heights, Ohio, Stati Uniti
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti
-
Duncansville, Pennsylvania, Stati Uniti
-
Wexford, Pennsylvania, Stati Uniti
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti
-
Greenville, South Carolina, Stati Uniti
-
-
Tennessee
-
Jackson, Tennessee, Stati Uniti
-
Nashville, Tennessee, Stati Uniti
-
-
Texas
-
Amarillo, Texas, Stati Uniti
-
Dallas, Texas, Stati Uniti
-
Fort Worth, Texas, Stati Uniti
-
Houston, Texas, Stati Uniti
-
Mesquite, Texas, Stati Uniti
-
Temple, Texas, Stati Uniti
-
Tyler, Texas, Stati Uniti
-
-
Virginia
-
Burke, Virginia, Stati Uniti
-
Reston, Virginia, Stati Uniti
-
-
Washington
-
Seattle, Washington, Stati Uniti
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients must have rheumatoid arthritis
- Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints
- Patients must have inadequate disease response to etanercept or adalimumab
- Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.
Exclusion Criteria:
- Patients who have a history of latent or active TB
- Have inflammatory disease other than rheumatoid arthritis
- Have had a chronic or recurrent infectious disease.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Altro: 001
Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10
Lasso di tempo: Week 10
|
Percent of patients who achieved EULAR response at Week 10.
EULAR response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999).
At a given visit, patients with a DAS28 score of ≤ 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is greater than 0.6; Or patients with a DAS28 score > 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is > 1.2.
|
Week 10
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase
Lasso di tempo: Week 26
|
Percent of patients who achieved EULAR response at Week 10 and maintained through Week 26 without infliximab dose increase
|
Week 26
|
|
Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26
Lasso di tempo: Week 26
|
Percent of patients who achieved EULAR response at Week 26, regardless of EULAR response status at Weeks 10, 14, and 22, with or without dose increase prior to Week 26
|
Week 26
|
|
Change From Baseline in Physical Function (HAQ)
Lasso di tempo: Week 10
|
Change from baseline in physical function (HAQ) at Week 10.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 10 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 10
|
|
Change From Baseline in Physical Function (HAQ)
Lasso di tempo: Week 26
|
Change from baseline in physical function (HAQ) at Week 26.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 26 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 26
|
|
Percent of Patients Who Achieved ACR20 at Week 10
Lasso di tempo: Week 10
|
Percent of patients who achieved ACR20 at Week 10.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 10
|
|
Percent of Patients Who Achieved ACR20 at Weeks 26.
Lasso di tempo: Week 26
|
Percent of patients who achieved ACR20 at Weeks 26.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 26
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CR013879
- C0168Z05 (Altro identificatore: Centocor Ortho Biotech Services, L.L.C.)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .